Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol.14, Issue 20s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Leveraging Artificial Intelligence for the Prevention and Control of Infectious Diseases

Shagun Sawhney[1], Arindam Adhikary[2*], Inkashaf Alam[3], Kanisheka Sharma[4]

[1]Department of Medical Laboratory Sciences, USAHS, Rayat Bahra University, Mohali, India.
Email ID : Shagunsawhney2001@gmail.com
[2]Department of Medical Laboratory Sciences, USAHS, Rayat Bahra University, Mohali, India
Email ID : a.adhikary88@gmail.com
[3]Department of Medical Laboratory Technology UIAHS Chandigarh University Mohali India.
Email ID : inkashafalam2@gmail.com
[4]Department of Medical Laboratory Sciences, USAHS, Rayat Bahra University, Mohali, India.
Email ID : kanisheka121@gmail.com
Corresponding Author:
Arindam Adhikary

.Cite this paper as Shagun Sawhney, Arindam Adhikary, Inkashaf Alam, Kanisheka Sharma (2025) Leveraging Artificial Intelligence for the Prevention and Control of Infectious Diseases..Journal of Neonatal Surgery, 14, (20s) 1014-1018

ABSTRACT
Infection diseases caused by pathogenic microorganisms, such as bacteria, viruses, fungi, and parasite, continue to be a significant global health concern. This problem is made worse by the lack of quick diagnostics and the rapid increase in antibiotic resistance. Through quantitative modelling, sequencing and the programmability of biology molecules like proteins, peptides and nucleic acids, advances in systems and synthetic biology have made it possible to develop new anti-infective treatments, vaccines, and diagnostic platforms. By enabling data-driven prediction, optimization, and analysis across various biology domains, these developments are being accelerated by powerful tool like machine learning and AI. Machine learning models have contributed to the discovery of new antimicrobial compounds, including graph-based predications, aptamers, and other alternative modalities. Additionally, machine learning techniques have guided the development of vaccines, predicated virulence and immunogenicity, enhanced our understanding of host-pathogen interactions, and enabled the automatic interpretation of data from mass spectrometry sequencing and microscopy. CRISPR-based sensors, toehold switches, and rapid susceptibility testing is example of AI-integrated diagnostics that have the potential to detect emerging infections more quickly, portably, and easily. Notwithstanding advancements, problems with data quality, model generalizability, bias reduction and clinical validation still exist. It is anticipated that as synthetic biology and next generation AI continue to be integrated, therapeutic discovery will progress, diagnostic precision will increase, and global capabilities for fighting infectious diseases will be strengthened

Keywords: Artificial Intelligence (AI), Machine Learning (ML), Antimicrobial peptide (AMPs), Antimicrobial susceptibility testing (AST)..

1. INTRODUCTION

Infectious diseases, which can spread directly or indirectly from person to person, are caused by pathogenic microorganisms such bacteria, viruses, parasites, viruses, parasites, or fungus[1]. These difficulties are made worse by limitation to the quick and precise detection of infection as well as growing antibiotic resistance. These issues have been the focus of basic research, which has produced anti-infective treatments, preventative strategies and quick and precise diagnostic instruments. Synthetic biology approaches and systems, in particular, having produce medical advancements and biotechnological that have improved are ability to treat infectious disease. These advancements include diagnostics, vaccines, modalities, and drug treatment. The two significant advances that gave birth to the field of systems and synthetic biology have been the elaboration and production of quantitative biological theories and data of wet lab work, sequencing and systems level production, and other biomolecules, which allow control of biology. The development and synthesis of quantitative biological theory and data from wet lab expedite AI is a technology that enables machines to perform tasks that previously needed human intelligence, such as learning thinking and problem solving[2]. In this review we address key areas where AI based methods applied to synthetic biology and systems are significantly advancing are investigation to combat transmissible disease..

AI for anti-infective discovery of drug

Drug resistances have made anti-infective medications which include anti-parasite, anti-bacterial, anti-fungal- less effective treatments. New anti-effective therapy is therefore desperately needed specially those that represent previously unheard-of chemical spaces or therapeutic modalities. A wide range of people and businesses in many different industries use AI and machine learning from individuals using smart phones as virtual assistance to major corporations in manufacturing, retail, healthcare and finance. The main advantage of AI and machine learning are in increased efficiency through automation, better decision making from data analysing and use data to train machine to make predictions because most antibiotics may not be classified as medications, the number of tiny molecules that resemble pharmaceuticals is almost limitless [up to ~1060], and may even be greater[3]. Focusing on phenotypes raises the possibility that anti-infective medications have polypharmacologic effects and that different macromolecular therapeutic targets may incorporate biological information. Second, most antibiotic drugs are macromolecules with chemical structures that may be represented mathematically as structures with sides and edges[4]. Other programmed techniques, such as antimicrobial peptide (AMPs) and target-binding nucleic acids knows as aptamers, are presently being developed[5]. This biological tractability stands in stark contrast to complicated illnesses like dementia of neurons, for which our lack of complete logical understanding continues to be a significant barrier. Compared to human cell types, the protein and gene network of even simple eukaryotes, viruses, bacteria are better understood and have larger databases, which may enable ML- driven methods to better discover pharmacological mechanisms of action and produce predictions that are more accurate. In order to construct graph neural network models that can predict the antibacterial capabilities of small compounds like helicine, based on their chemical structures, we previously assessed a set of small molecules for their capacity to suppress the development of Escherichia coli. However, these designs were most successful in predicting compounds belonging to well known antibiotic classes like quinolones and lactams. Different strategies are required to access previously unexplored sequence spaces. These kinds of models will assist in identifying only the most promising therapeutic candidates. For ML model training and benchmarking, it is also crucial to provide “negative” data, such as tested compounds that are inactive. Additionally, when Machine learning models are used to difficult test sets, it is crucial to clearly communicate their limitations (e.g. through confidence information).

Artificial intelligence for related to infections contexts and infection biology

Pathogens that are eukaryotic, viral infect or bacterial a variety of host and cause intricate host reaction. The host`s immune system, the pathogen burden, treatments given, and other biological considerations all affect how an infection develops. In order to identify important traits and molecular patterns that support host-pathogen interactions and immune responses, supervised ML techniques have been applied to both structure and unstructured datasets, such as nucleic acids, proteins, glycans, and cellular phenotypes[6]. Many supervised and unsupervised ML models have been used to predict immunogenicity, evaluate pathogen killing, host cell adaptation and virulence, and identify genes and protein interactions associated with host cell alteration. Examples of these models include complex language models with random forest classifiers. In medical imaging, AI models can detect infections like pneumonia or tuberculosis (TB) on chest radiographs and CT scans with accuracy approaching expert radiologists, For example, in COVID-19 pneumonia, deep learning systems have achieved sensitivities of 60–95 % on test datasets, comparable to human radiologists (range 42–100 %)[7]. The creation of biological hypotheses may be guided and generalizability enhanced by machine learning models that can leverage structural information or make particular biological assumptions like the significance of semantics and syntax in biological sequences. Microscopy datasets related to infection biology have been effectively processed by machine learning. The datasets that underpin machine learning models the host cell that identify fungi, viruses, parasites and bacteria have been created using a variety of microscopy techniques, such as light and electron microscopy, by clarifying the development of using multi-color fluorescence microscopy to examine the characteristics of P. Falciparum using high-content imaging, in human red blood cell and phenogenomic data to identify virulence factors involved in the pathogenesis of mycobacterium abscesses, for instance these analyses have yielded insights into host-pathogen biology[8]. The diagram illustrates the ways of AI that assist research in the field of infectious diseases with the help of three significant areas: medical image interpretation, point-of-care diagnostics and next-generation sequencing shown in fig.1. Models for machine learning influenced many facts the creation of vaccines beyond Host-pathogen interaction. Sequences- based ML techniques can speed up the design of mRNA and nucleic acid vaccines and their synthesis and experimental validation can be completed quickly[9]. Computational predictions from AlphaFold or Rosetta Fold can also be added to protein structure-based vaccine development, such as challenging test protocols, generalizability, poor data quality, limited data availability.



Fig.1: The diagram illustrates the ways of AI that assist research in the field of infectious diseases with the help of three significant areas: medical image interpretation, point-of-care diagnostics and next-generation sequencing. These combined applications assist in ameliorating identification, examination and awareness of pathogens and infection mechanisms[10].

AI for artificial biology and diagnostics

Controlling the spread of infectious diseases requires prompt and accurate detection of infection and pathogen outbreak, as demonstrated by extensive testing efforts during the COVID-19 pandemic[11]. Our capacity to identify infectious and anticipate treatment resistance has greatly increased because to recent advancement in integrating Artificial learning combined with mass spectrometry, imaging, gene expression analysis, and artificial biology. Design that utilizes biology still depend on the engineering of genetic components and an understanding of biomolecules networks. Zika, Malaria, COVID-19, Ebola and other diseases have been detected using synthetic biology techniques that make use of CRISPR-Cas enzymes, enzymatic reaction, toehold switches. Beyond synthetic biology, machine learning has been applied to imaging-based diagnostics, mass spectrometry, and gene expression. Antimicrobial susceptibility testing (AST)has made use of diagnostics based on mass spectrometry and gene expression. Although standard, for fungi, viruses, parasite, bacteria culture-based AST can may require a few days to finish, AST is still crucial for guiding the use of anti-infective medications[12]. For acute systemic infections, like those that cause sepsis, this processing time is still too much time to effectively respond towards clinical needs. The creation of ML models that offer precise diagnoses in the medical field, the use of auto data from clinical and field-deployable diagnostics to increase accessibility and scope, and the ML -guided design and discovery of synthetic circuits that enable the creation of portable and low-cost diagnostics are all examples. However, for ML models to be used practically in clinical diagnoses, their accuracy must also be improved. To achieve high accuracy, future machine learning models will probably need to be trained on a lot of reliable data, carefully assessed for biases, and optimized in terms of architecture. These next-generation machine earning models can make more precise diagnoses with the aid of attention systems, multitask learning, transfer and other techniques[13].

2. CHALLENGES AND LIMITATION

Although the field of infectious-disease research is promising to integrate AI, machine learning, synthetic biology, there are still a number of challenges and limitations to these methods that prevent their widespread use in clinical applications. One of the obstacles is the quality of data, since most biological and clinical data is dirty, incomplete, or produced in non-standardized environments, which decreases the accuracy of AI result. The model generalizability is low, and algorithms tend to work in training datasets and do not work with different patient, rare pathogens or real-world clinical sample. Data bias such as poor sampling, batch effects or demographic imbalance may cause model outputs to be biased and diagnostic or treatment advice to be invalid. Moreover, there is little access to quality labelled data which limits the training of complex models particularly with emergent pathogens. The other important constraint is that most AI models lack transparency and interpretability and hence it is not easy to trust or establish the relevance of predictions by clinicians and biologists[14]. Clinical validation as well as regulatory approval in diagnostics is still a slow and resource-intensive process that slows the implementation of AI-based tools in healthcare. Practical issues also continue to tie AI system in laboratory processes, particularly in low-resource settings, where there might be a lack of computational resources, Lastly, machine learning-driven synthetic biology designs are limited to off-target effects, biological heterogeneity, safety, and scaling engineering designs to the real world[15].

3. CONCLUSION

New strategies that extend beyond the traditional therapeutic and diagnostic measures are necessary because of the increasing burden of infectious diseases and a rapid diffusion of antibiotic resistance. The convergence of AI with systems and synthetic biology is what enables faster drug discovery, enhanced host-pathogen interaction understanding, enhanced vaccine design, and faster and more convenient diagnostic solutions. The machine learning models based on chemical, genomic, structural and phenotypic data have been demonstrated to be useful in predicting biological behaviour, in identifying new anti-infective candidates, and optimizing engineered biological systems. On the same note, CRISPR-based detection, profiling of gene expression and imaging analytics are some examples of AI-enhanced diagnostic platforms that can potentially enhance diseases surveillance and reduce clinical turnaround time. Nevertheless, the barriers that will need to be overcome in order to unlock the full potential of these technologies will be related to the data quality, model interpretability, generalizability, and regulatory acceptance.

4. ACKNOWLEDGMENTS

We would like to acknowledge the department of Medical Laboratory Sciences (USAHS), Rayat Bahra University for providing the required facilities.

Funding: None

Conflict of Interest: None..

REFERENCES

[1.] J. Verhoef, K. Van Kessel, and H. Snippe, "Immune Response in Human Pathology: Infections Caused by Bacteria, Viruses, Fungi, and Parasites," Nijkamp Parnham's Princ. Immunopharmacol. Fourth Revis. Ext. Ed., pp. 165–178, Jan. 2019, doi: 10.1007/978-3-030-10811-3_10/FIGURES/5.

[2] M. Soares, "Symbiotic relationships in environments of change: The potential of biological interactions in Artificial Intelligence," Mar. 2025.

[3] A. A. Theodosiou and R. C. Read, "Artificial intelligence, machine learning and deep learning: Potential resources for the infection clinician," J. Infect., vol. 87, no. 4, pp. 287–294, Oct. 2023, doi: 10.1016/J.JINF.2023.07.006.

[4] W. Al Borhani, "G216072 Aptameric Biosensors for the Detection of Apramycin and Amoxicillin Antibiotics in Water".

[5] C. R. Chung, T. R. Kuo, L. C. Wu, T. Y. Lee, and J. T. Horng, "Characterization and identification of antimicrobial peptides with different functional activities," Brief. Bioinform., vol. 21, no. 3, pp. 1098–1114, May 2020, doi: 10.1093/BIB/BBZ043.

[6] R. Sahragard, M. Arabfard, and A. Najafi, "Predicting host-pathogen interactions with machine learning algorithms: A scoping review," Infect. Genet. Evol., vol. 130, p. 105751, Jun. 2025, doi: 10.1016/J.MEEGID.2025.105751.

[7] S. Abbara, Y. Crabol, J. G. de Bouillé, A. Dinh, and D. Morquin, "Artificial intelligence and infectious diseases: Scope and perspectives," Infect. Dis. Now, vol. 55, no. 7, 2025, doi: 10.1016/j.idnow.2025.105131.

[8] C. Zhang et al., "Deep learning for microscopic examination of protozoan parasites," Comput. Struct. Biotechnol. J., vol. 20, pp. 1036–1043, Jan. 2022, doi: 10.1016/J.CSBJ.2022.02.005.

[9] S. M. Castillo-Hair and G. Seelig, "Machine Learning for Designing Next-Generation mRNA Therapeutics," Acc. Chem. Res., vol. 55, no. 1, pp. 24–34, 2022, doi: 10.1021/acs.accounts.1c00621.

[10] C. Dong, Y. Liu, J. Nie, X. Zhang, F. Yu, and Y. Zhou, "Artificial Intelligence in Infectious Disease Diagnostic Technologies," Diagnostics 2025, Vol. 15, Page 2602, vol. 15, no. 20, p. 2602, Oct. 2025, doi: 10.3390/DIAGNOSTICS15202602.

[11] R. W. Peeling, D. L. Heymann, Y. Y. Teo, and P. J. Garcia, "Diagnostics for COVID-19: moving from pandemic response to control," Lancet, vol. 399, no. 10326, pp. 757–768, Feb. 2022, doi: 10.1016/S0140-6736(21)02346-1.

[12] E. Wenzler, M. Maximos, T. E. Asempa, L. Biehle, A. N. Schuetz, and E. B. Hirsch, "Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists," Pharmacotherapy, vol. 43, no. 4, pp. 264–278, Apr. 2023, doi: 10.1002/PHAR.2781;PAGE:STRING:ARTICLE/CHAPTER.

[13] D. J. Park, M. Woo Park, H. Lee, Y.-J. Kim, Y. Kim, and Y. H. Park, "Development of machine learning model for diagnostic disease prediction based on laboratory tests," Sci. Reports |, vol. 11, p. 7567, 123AD, doi: 10.1038/s41598-021-87171-5.

[14] V. Hassija, V. Chamola, A. Mahapatra, A. Singal, D. Goel, and K. Huang, "Interpreting Black - Box Models : A Review on Explainable Artificial Intelligence," Cognit. Comput., pp. 45–74, 2024, doi: 10.1007/s12559-023-10179-8.

[15] D. A. Tuan, P. Vu, N. Uyen, T. Ho, N. Vo, and T. Nhan, "Hybrid Quorum Sensing and Machine Learning Systems for Precision Gene Regulation : Revolutionizing Synthetic Biology and Autonomous Therapeutic Applications," pp. 1–55,

2024.